Mechanisms of Resistance to Antibody–Drug Conjugates
Rachel O. Abelman(Massachusetts General Hospital), Aditya Bardia(Harvard University), Laura M. Spring(Massachusetts General Hospital), Bogang Wu(George Washington University), Leif W. Ellisen(Harvard University)
Cited by 135
Related Papers
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
|New England Journal of Medicine|2019|1k
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
|Journal of Clinical Oncology|2010|983
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846
Hypoxia regulates TSC1/2–mTOR signaling and tumor suppression through REDD1-mediated 14–3–3 shuttling
|Genes & Development|2008|696